How Biotechs Should Choose eConsent for Immunology Trials
Direct answer
Biotechs running immunology and autoimmune trials should choose eConsent that manages optional consent for biomarker and future-use samples, pushes reconsent quickly after safety or dosing amendments, and carries participants smoothly into long-term extension studies. For a lean biotech team, fast self-serve setup, pre-validated Part 11 compliance, and sponsor-owned records matter just as much.
Why is consent complex in immunology trials?
Immunology and autoimmune programs, from rheumatoid arthritis and lupus to inflammatory bowel disease, tend to have long timelines and evolving protocols. Composite disease activity scores get added mid-study, dosing algorithms shift as safety data comes in, and a single protocol amendment can touch dozens of forms across every site. When those changes affect risk or procedures, participants usually need to reconsent.
Many of these trials also collect blood or tissue samples for biomarker and genetic research. Consent for storage and future use of samples is typically optional, and participants can still take part in the main study if they decline. For genomic research, NIH expects explicit consent for future research use and broad sharing of genomic and phenotypic data in studies it funds. An eConsent platform needs to record each of those choices separately and make them visible to the lab and data teams.
Finally, many immunology programs roll participants from a core study into an open-label or long-term extension, which means a new consent at a time when participants may already be months into treatment.
What do regulators expect from eConsent?
Electronic consent must meet the same requirements as paper consent. FDA and OHRP guidance on electronic informed consent covers drugs, biologics, and devices, and points to 21 CFR Part 50 for consent, Part 56 for IRBs, and Part 11 for electronic records and signatures. Validation commonly involves installation, operational, and performance qualification (IQ/OQ/PQ), and biotechs often look for platforms that come pre-validated with a validation package.
What should biotechs look for in eConsent?
Separate optional consents
Distinct, trackable choices for biomarker samples, genetic testing, future use, and data sharing, with withdrawal of any one handled cleanly.
Fast, version-controlled reconsent
Push a new consent version to every affected participant after an amendment and see who has signed, by version and site.
Extension study handoff
Consent for a long-term extension that links to the participant's core study record.
Multimedia and comprehension checks
Short videos and plain-language explanations of biologic risks such as infection, injection-site reactions, or dosing changes.
Self-serve setup
Biotechs often weigh rapid setup alongside strict compliance with Part 11 and EU CTR, so a small team should be able to build and amend consent forms without vendor programming.
Pilot first
TransCelerate notes that small-scale pilots can help identify eConsent strengths and limitations before larger rollouts.
Comparing eConsent platforms for biotechs running immunology trials
| Vendor | Known for | Fit for biotech and immunology trials |
|---|---|---|
| Curebase | Structured eConsent, eCOA/ePRO, and EDC on one data model | A strong fit for biotechs that want optional sample consents, reconsent status, and extension enrollment visible in the same record as clinical data |
| Medrio | eConsent supporting in-clinic, remote, and hybrid workflows with paper-consent upload | A fit for early-phase biotech studies that mix consent modes |
| Medidata Consent | eConsent integrated with Rave EDC for onsite and remote consent | A fit for biotechs already running on Rave |
| Signant SmartSignals | Interactive slides, video, audio, and LAR signatures | A fit for studies that need rich multimedia education about biologic risks |
What should biotechs ask eConsent vendors about immunology studies?
- How are optional consents for biomarker, genetic, and future-use samples recorded, and how is a withdrawal of one choice communicated to the lab?
- How quickly can we push a new consent version after a dosing or safety amendment, and how do we track completion by site?
- Can extension study consent link to the participant's core study record?
- What validation documentation comes with the platform, and how much of IQ/OQ/PQ is already done?
- Who owns the consent records and templates if we change vendors?
Where does Curebase fit for biotechs running immunology trials?
Curebase eConsent runs on the same data model as its eCOA/ePRO and EDC. For a biotech running an autoimmune program, that means sample consent choices, reconsent status, and extension enrollment sit next to flare diaries and visit data. A small team can see in one place who has signed the current version before a dosing change takes effect, which keeps the study compliant without extra reconciliation.
Frequently asked questions
Why do immunology trials need frequent reconsent?
Immunology programs often run for a long time, and dosing or safety information can change as data comes in. When an amendment affects risk or procedures, participants typically need to review and sign an updated consent form.
How does eConsent handle optional biomarker or genetic sample consent?
Good eConsent platforms record each optional choice separately, such as sample storage, genetic testing, and future research use. This lets participants decline one option and still join the main study, and keeps lab teams aligned with what each person agreed to.
Is eConsent allowed for FDA-regulated biologic trials?
Yes. FDA and OHRP guidance on electronic informed consent covers drugs, biologics, and devices, as long as the process meets 21 CFR Part 50, Part 56, and Part 11 requirements.
What should small biotechs prioritize in an eConsent vendor?
Priorities usually include fast self-serve setup, pre-validated Part 11 compliance, version-controlled reconsent, and sponsor ownership of records. Clear handling of optional sample consents is especially important in immunology.
How does eConsent support long-term extension studies?
eConsent can present the extension consent as participants finish the core study and link it to their existing record. That keeps the participant's history connected and reduces paperwork for sites.
Does Curebase offer eConsent for biotech immunology trials?
Yes. Curebase eConsent runs on one data model with its eCOA/ePRO and EDC, so optional consents, reconsent history, and clinical data stay together in one connected record.
